WuXi AppTec DMPK

WuXi AppTec DMPK leverages over 18 years of experience and a track record of over 1,700 successful IND filings. Operating in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), it specializes in pharmacokinetics studies. When you partner with WuXi AppTec for drug discovery and development services, you gain access to an integrated worldwide network of facilities that offer a full range of discovery screening, preclinical development, and clinical drug metabolism and pharmacokinetics (DMPK) platforms and services. These include in vitro absorption, distribution, metabolism, excretion (ADME) studies, in vivo pharmacokinetic studies, metabolite profiling and identification studies, radiolabeled compound synthesis, radiolabeled in vivo ADME studies, and Non-GLP bioanalysis.